P. Hoskins

发表

Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study.

E. Eisenhauer, D. Tu, J. Squire, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma.

Randy D Gascoyne, Laurie H Sehn, R. Gascoyne, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

International Prognostic Score in advanced-stage Hodgkin's lymphoma: altered utility in the modern era.

R. Gascoyne, L. Sehn, J. Connors, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Progression-free survival in advanced ovarian cancer: a Canadian review and expert panel perspective.

M. Buyse, H. Mackay, A. Oza, 2011, Current oncology.

Triple cytotoxic therapy for advanced ovarian cancer: a failed application, not a failed strategy.

P. Hoskins, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Reuse of carboplatin and paclitaxel in patients with relapsed endometrial cancer--the British Columbia Cancer Agency experience.

N. Le, P. Hoskins, Mona Mazgani, 2008, Gynecologic oncology.

Use of systemic therapy in women with recurrent ovarian cancer--development of a national clinical practice guideline.

G. Browman, L. Elit, P. Ghatage, 2007, Gynecologic oncology.

Front-Line Therapy with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) Followed by 2 Years of Rituximab Maintenance for Follicular Lymphoma (FL) Is Associated with Excellent Outcomes and Improved Progression-Free Survival (PFS) In Comparison to No Maintenance

R. Gascoyne, L. Sehn, J. Connors, 2010 .

Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: Potential implications for future prophylaxis recommendations

U. Steinbrecher, E. Yoshida, J. Law, 2005, Leukemia & lymphoma.

The treatment of primary central nervous system lymphoma in 122 immunocompetent patients

R. Gascoyne, L. Sehn, J. Connors, 2005, Cancer.

Preoperative radiotherapy for inoperable stage II endometrial cancer: insights into improving treatment and outcomes.

J. Kwon, C. Aquino-Parsons, P. Hoskins, 2013, Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC.

The importance of adjuvant chemotherapy and pelvic radiotherapy in high-risk early stage endometrial carcinoma.

A. Tinker, J. Kwon, C. Aquino-Parsons, 2013, Gynecologic oncology.

The Role of Platins in Newly Diagnosed Endometrial Cancer

P. Hoskins, 2009 .

Time for a level playing field: inequalities in regulatory/approval processes—the example of bevacizumab in epithelial ovarian cancer.

Dianne Miller, M. Fung-Kee-Fung, P. Hoskins, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The ‘failure free interval’ defines the likelihood of resistance to carboplatin in patients with advanced epithelial ovarian cancer previously treated with cisplatin: relevance to therapy and new drug testing

K. Swenerton, S. O'Reilly, P. Hoskins, 1991, International Journal of Gynecologic Cancer.

Canadian cost-effectiveness model of BRCA-driven surgical prevention of breast/ovarian cancers compared to treatment if cancer develops

M. Dyer, P. Hoskins, M. Hurry, 2020, International Journal of Technology Assessment in Health Care.

Technical update on tissue morcellation during gynaecologic surgery: its uses, complications, and risks of unsuspected malignancy.

Dianne Miller, M. Bernardini, W. Gotlieb, 2015, Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC.

Adjuvant Treatment of Early Ovarian Clear Cell Carcinoma: A Population-Based Study of Whole Abdominal Versus Pelvic Nodal Radiotherapy.

A. Tinker, P. Hoskins, Soumyajit Roy, 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

Phase II Study of Sequential Topotecan and Etoposide in Patients with Intermediate Grade Non-Hodgkin's Lymphoma: A National Cancer Institute of Canada Clinical Trials Group Study

E. Eisenhauer, B. Zanke, M. Crump, 2002, Leukemia & lymphoma.

Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study.

E. Eisenhauer, B. Zee, S. Beare, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia.

H. Mackay, A. Oza, H. Hirte, 2012, Gynecologic oncology.

Dalteparin low molecular weight heparin (LMWH) in ovarian cancer: a phase II randomized study.

P. Liaw, L. Elit, M. Levine, 2012, Thrombosis research.

Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel.

E. Eisenhauer, A. Oza, D. Provencher, 2010, Journal of the National Cancer Institute.

Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148.

E. Eisenhauer, A. Oza, D. Provencher, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Factors predictive of survival after first relapse or progression in advanced epithelial ovarian carcinoma: a prediction tree analysis-derived model with test and validation groups.

D. Tu, J. Pater, P. Hoskins, 1998, Gynecologic oncology.

Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy.

J. Hainsworth, B. Zee, J. Krook, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

In search of an optimal regimen for elderly patients with advanced-stage diffuse large-cell lymphoma: results of a phase II study of P/DOCE chemotherapy.

J. Connors, R. Klasa, P. Hoskins, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized study of sequential cisplatin-topotecan/carboplatin-paclitaxel versus carboplatin-paclitaxel: effects on quality of life

E. Eisenhauer, M. Brundage, D. Tu, 2016, Supportive Care in Cancer.

Pegylated liposmal doxorubicin prolongs survival compared to topotecan as second-line treatment in women with platinum-sensitive ovarian cancer

P. Hoskins, 2002 .

Phase II feasibility study of sequential couplets of Cisplatin/Topotecan followed by paclitaxel/cisplatin as primary treatment for advanced epithelial ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group Study.

E. Eisenhauer, A. Oza, I. Vergote, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I study of bi-weekly paclitaxel/cisplatin as initial therapy for advanced ovarian cancer. A study of the National Cancer Institute of Canada Clinical Trials Group.

E. Eisenhauer, K. Swenerton, G. Batist, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Brief C hemotherapy a nd I nvolved-Region I rradiation f or Limited-Stage D iffuse L arge-Cell L ymphoma: A n 1 8-Year Experience F rom t he B ritish C olumbia C ancer A gency

R. Gascoyne, J. Connors, S. Sutcliffe, 2002 .

Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: an 18-year experience from the British Columbia Cancer Agency.

R. Gascoyne, J. Connors, S. Sutcliffe, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Follow-Up of Epithelial Ovarian Cancer: Overdue For A Major Rethink

P. Hoskins, 2013, Current Oncology Reports.

CA 125 normalization with chemotherapy is independently predictive of survival in advanced endometrial cancer.

N. Le, P. Hoskins, R. Correa, 2011, Gynecologic oncology.

MACOP-B and VACOP-B in diffuse large cell lymphomas and MOPP/ABV in Hodgkin's disease.

J. Connors, P. Hoskins, P. Klimo, 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

Dexamethasone improves the efficacy of granisetron in the first 24 h following high-dose cisplatin chemotherapy

F. Shepherd, D. Walde, L. Yelle, 1995, Supportive Care in Cancer.

The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy.

J. Hainsworth, J. Krook, D. Walde, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Which is the better surgical strategy for newly diagnosed epithelial ovarian cancer: primary or interval debulking?

P. Hoskins, 2011, Current opinion in oncology.

Dose-dense paclitaxel in advanced ovarian cancer.

A. Tinker, A. Kumar, P. Hoskins, 2015, Clinical oncology (Royal College of Radiologists (Great Britain)).

Carboplatin plus paclitaxel for advanced or recurrent uterine malignant mixed mullerian tumors. The British Columbia Cancer Agency experience.

A. Tinker, N. Le, K. Swenerton, 2008, Gynecologic oncology.

Carboplatin and paclitaxel for advanced and recurrent cervical carcinoma: the British Columbia Cancer Agency experience.

A. Tinker, K. Swenerton, P. Hoskins, 2005, Gynecologic oncology.

Preoperative tumor markers at diagnosis in women with malignant mixed müllerian tumors/carcinosarcoma of the uterus

N. Le, P. Hoskins, 2007, International Journal of Gynecologic Cancer.

Early-Stage Endometrioid Ovarian Carcinoma: Population-Based Outcomes in British Columbia

A. Tinker, N. Le, Aalok Kumar, 2014, International Journal of Gynecologic Cancer.

Chemotherapy is of Value in Second Line and Beyond, Relapsed High-grade, Serous Epithelial Ovarian Cancer: An Analysis of Outcomes Obtained With Oral Etoposide

N. Le, Aalok Kumar, Jennifer L. Santos, 2016, American journal of clinical oncology.

A phase II study of aflibercept (VEGF trap) in recurrent or metastatic gynecologic soft-tissue sarcomas: A study of the Princess Margaret Hospital Phase II Consortium.

H. Mackay, A. Oza, R. Buckanovich, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Single or two drug combination therapy as initial treatment for low risk, gestational trophoblastic neoplasia. A Canadian analysis.

N. Le, Aalok Kumar, P. Hoskins, 2020, Gynecologic oncology.

Combined methotrexate-dactinomycin: an effective therapy for low-risk gestational trophoblastic neoplasia.

K. Swenerton, H. Steed, P. Hoskins, 2012, Gynecologic oncology.

Cisplatin/etoposide chemotherapy for recurrent or primarily advanced cervical carcinoma.

K. Swenerton, P. Hoskins, J. Pike, 1997, Gynecologic Oncology.

Carboplatin plus paclitaxel for advanced or recurrent uterine malignant mixed mullerian tumors. The British Columbia Cancer Agency experience.

A. Tinker, N. Le, K. Swenerton, 2008, Gynecologic oncology.

Population-based treatment and outcomes of Stage I uterine serous carcinoma.

A. Tinker, J. Kwon, C. Aquino-Parsons, 2014, Gynecologic oncology.

Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study.

K. Swenerton, P. Hoskins, P. Lim, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

P a c litaxel a nd C arboplatin, A lone o r W ith I rradiation, i n Advanced o r R ecurrent E ndometrial C ancer: A P hase I I S tudy

K. Swenerton, P. Hoskins, P. Lim, 2001 .

Small cell of the ovary, hypercalcemic type -- analysis of combined experience and recommendation for management. A GCIG study.

J. Ledermann, G. Rustin, M. Friedlander, 2006, Gynecologic oncology.

The International Prognostic Factor Project Score (IPS) in Advanced Stage Hodgkin Lymphoma Has Limited Utility in Patients Treated in the Modern Era.

R. Gascoyne, L. Sehn, J. Connors, 2009 .

Outcome of Patients with Chemotherapy Refractory and Early Progressive Diffuse Large B Cell Lymphoma After R-CHOP Treatment

R. Gascoyne, L. Sehn, J. Connors, 2010 .

Hodgkin Lymphoma Patients with Stage II B or Stage II Bulky Disease Have Advanced Disease and Should Not Be Included In Limited Stage Trials

R. Gascoyne, L. Sehn, J. Connors, 2010 .

Survival Benefit of Adjuvant Radiotherapy: An Analysis of Low-Stage Invasive Ovarian Mucinous Carcinomas

A. Tinker, N. Le, K. Swenerton, 2017, International Journal of Gynecologic Cancer.

The use of FDG-PET to guide consolidative radiotherapy in patients with advanced-stage Hodgkin lymphoma with residual abnormalities on CT scan following ABVD chemotherapy.

R. Gascoyne, K. Savage, F. Bénard, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The impact of initial treatment of advanced stage indolent lymphoma on the risk of transformation.

R. Gascoyne, K. Savage, J. Connors, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Small-cell carcinoma of the cervix: fourteen years of experience at a single institution using a combined-modality regimen of involved-field irradiation and platinum-based combination chemotherapy.

K. Swenerton, C. Aquino-Parsons, P. Hoskins, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic variables in patients with diffuse large-cell lymphoma treated with MACOP-B.

J. Connors, J. Spinelli, P. Hoskins, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Missed therapeutic and prevention opportunities in women with BRCA‐mutated epithelial ovarian cancer and their families due to low referral rates for genetic counseling and BRCA testing: A review of the literature

W. Gotlieb, P. Hoskins, 2017, CA: a cancer journal for clinicians.

Paraneoplastic erythropoietin-induced polycythemia associated with small lymphocytic lymphoma.

P. Tsang, P. Hoskins, A. Al-Tourah, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

B. Monk, K. Jardon, I. Vergote, 2019, The New England journal of medicine.

Controversies in the Management of Endometrial Cancer

A. Obermair, J. Magrina, P. Hoskins, 2010, Obstetrics and gynecology international.

Ovarian cancer screening: UKCTOCS trial

W. Gotlieb, P. Hoskins, 2016, The Lancet.

The role of the fallopian tube in ovarian cancer.

A. Tinker, D. Huntsman, K. Swenerton, 2012, Clinical advances in hematology & oncology : H&O.

Evolution of genetic assessment for BRCA-associated gynaecologic malignancies: a Canadian multisociety roadmap

W. Meschino, H. Hirte, M. Bernardini, 2018, Journal of Medical Genetics.

Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group.

H. Mackay, E. Eisenhauer, A. Oza, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Assessment of Her-1, Her-2, and Her-3 Expression and Her-2 Amplification in Advanced Stage Ovarian Carcinoma

D. Huntsman, Dianne Miller, C. Gilks, 2005, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

Low-stage ovarian clear cell carcinoma: population-based outcomes in British Columbia, Canada, with evidence for a survival benefit as a result of irradiation.

A. Tinker, N. Le, K. Swenerton, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of erlotinib (OSI 774) in women with recurrent or metastatic endometrial cancer: NCIC CTG IND-148.

E. Eisenhauer, A. Oza, J. Dancey, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma.

J C Reed, R. Gascoyne, D. Horsman, 1997, Blood.

Prognostic implications of extranodal involvement in patients with diffuse large B-cell lymphoma treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone

R. Gascoyne, L. Sehn, J. Connors, 2010, Leukemia & lymphoma.

Targeted surgical prevention of epithelial ovarian cancer is cost effective and saves money in BRCA mutation carrying family members of women with epithelial ovarian cancer. A Canadian model.

M. Dyer, P. Hoskins, M. Hurry, 2019, Gynecologic oncology.

Inadequate Rates of BRCA Testing with its Negative Consequences for Women with Epithelial Ovarian Cancer and their Families: an Overview of the Literature.

P. Hoskins, 2018, Clinical oncology (Royal College of Radiologists (Great Britain)).

S0266462319003519jra 104..112

M. Dyer, P. Hoskins, M. Hurry, 2020 .

Long-term outcomes of R-CEOP show curative potential in patients with DLBCL and a contraindication to anthracyclines.

R. Gascoyne, L. Sehn, J. Connors, 2021, Blood advances.

Gemcitabine, dexamethasone, and cisplatin (GDP) is an effective and well-tolerated salvage therapy for relapsed/refractory diffuse large B-cell lymphoma and Hodgkin lymphoma

R. Gascoyne, L. Sehn, J. Connors, 2017, Leukemia & lymphoma.

Clinical Trials and Observations

R. Gascoyne, L. Sehn, J. Connors, 2005 .

Low-grade serous carcinoma (LGSC): A Canadian multicenter review of practice patterns and patient outcomes.

A. Tinker, M. Köbel, D. Provencher, 2020, Gynecologic oncology.

Phase I (safety assessment) of durvalumab (MEDI4736) with focal sensitizing radiotherapy in platinum resistant ovarian, primary peritoneal or fallopian tube epithelial carcinoma.

A. Tinker, S. Lheureux, Mitchell C C Liu, 2019, Journal of Clinical Oncology.

First application of the Automated QUantitative Analysis (AQUA) technique to quantify PTEN protein expression in ovarian cancer: A correlative study of NCIC CTG OV.16.

E. Eisenhauer, D. LeBrun, D. Tu, 2016, Gynecologic oncology.

Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trials Group.

D. Johnston, D. Osoba, F. Shepherd, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Low junctional adhesion molecule-A expression is associated with an epithelial to mesenchymal transition and poorer outcomes in high-grade serous carcinoma of uterine adnexa

A. Mes-Masson, A. Oza, M. Köbel, 2020, Modern Pathology.

Treatment of advanced epithelial ovarian cancer: past, present and future.

P. Hoskins, 1995, Critical reviews in oncology/hematology.

Niraparib therapy in patients with newly diagnosed advanced ovarian cancer (PRIMA/ENGOT-OV26/GOG-3012 study)

Richard G. Moore, B. Monk, M. Mirza, 2019, Annals of Oncology.

Outcome of patients with primary refractory diffuse large B cell lymphoma after R-CHOP treatment

R. Gascoyne, L. Sehn, K. Savage, 2015, Annals of Hematology.

Taxol is active in platinum-resistant endometrial adenocarcinoma.

P. Hoskins, K. Swenerton, H. L. Woo, 1996, American journal of clinical oncology.

Exploring palliative treatment outcomes in women with advanced or recurrent ovarian clear cell carcinoma.

A. Tinker, K. Swenerton, C. Gilks, 2011, Gynecologic oncology.

A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer

K. Swenerton, Dianne Miller, T. Whiteside, 2004, International Journal of Gynecologic Cancer.

R-CHOP with Etoposide Substituted for Doxorubicin (R-CEOP): Excellent Outcome in Diffuse Large B Cell Lymphoma for Patients with a Contraindication to Anthracyclines.

R. Gascoyne, L. Sehn, J. Connors, 2009 .

Advanced diffuse large-cell lymphoma treated with 12-week combination chemotherapy: natural history of relapse after initial complete response and prognostic variables defining outcome after relapse.

R. Gascoyne, N. Le, J. Connors, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Revised International Prognostic Index (R-IPI) Is a Better Predictor of Outcome Than the Standard IPI for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Rituximab and CHOP (R-CHOP).

R. Gascoyne, L. Sehn, J. Connors, 2005 .

FDG-PET Scan Guided Consolidative Radiation Therapy Optimizes Outcome In Patients with Advanced-Stage Diffuse Large B-Cell Lymphoma (DLBCL) with Residual Abnormalities on CT Scan Following R-CHOP

R. Gascoyne, L. Sehn, J. Connors, 2010 .

Oral etoposide is active against platinum-resistant epithelial ovarian cancer.

K. Swenerton, P. Hoskins, K. Swenerton, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II trial of intravenous etoposide (VP-16-213) in epithelial ovarian cancer resistant to cisplatin or carboplatin: clinical and serological evidence of activity

K. Swenerton, P. Hoskins, E. McMurtrie, 1991, International Journal of Gynecologic Cancer.

Small cell carcinoma of the cervix treated with concurrent radiotherapy, cisplatin, and etoposide.

K. Swenerton, P. Hoskins, E. McMurtrie, 1995, Gynecologic oncology.

Ten-year outcome of patients with advanced epithelial ovarian carcinoma treated with cisplatin-based multimodality therapy.

K. Swenerton, J. L. Benedet, P. Hoskins, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

‘Moderate-risk’ ovarian cancer (stage I, grade 2; stage II, grade 1 or 2) treated with cisplatin chemotherapy (single agent or combination) and pelvi-abdominal irradiation

N. Le, K. Swenerton, P. Hoskins, 1993, International Journal of Gynecologic Cancer.

Platinum plus cyclophosphamide plus radiotherapy is superior to platinum alone in ‘high-risk’ epithelial ovarian cancer (residual negative and either stage I or II, grade 3, or stage III, any grade)

N. Le, K. Swenerton, P. Hoskins, 1994, International Journal of Gynecologic Cancer.

Identifying patients unlikely to benefit from further chemotherapy: a descriptive study of outcome at each relapse in ovarian cancer.

N. Le, P. Hoskins, 2005, Gynecologic oncology.

Malignant lymphomas in the elderly.

J. Connors, N. Macpherson, R. Klasa, 1997, Clinics in geriatric medicine.

17 Safety and patient-reported outcomes in patients receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial

K. Jardon, P. Follana, F. Heitz, 2020 .

Predicting outcome after initial relapse of epithelial ovarian cancer: can we identify patients who will not benefit from further therapy?

E. Eisenhauer, M. Glabbeke, D. Tu, 1999 .

Gemcitabine, Dexamethasone, and Cisplatin (GDP) Is An Effective and Well-Tolerated out-Patient Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Hodgkin Lymphoma (HL)

R. Gascoyne, L. Sehn, J. Connors, 2010 .

Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel.

E. Eisenhauer, A. Oza, D. Provencher, 2010, Journal of the National Cancer Institute.

Intraperitoneal chemotherapy for patients with advanced ovarian cancer: a review of the evidence and standards for the delivery of care.

D. Provencher, B. Rosen, T. Oliver, 2007, Gynecologic oncology.

"MECCA": a developmental, dose-intensive, non-cross-resistant platinum-based chemotherapy for advanced ovarian cancer.

K. Swenerton, P. Hoskins, E. McMurtrie, 1996, Gynecologic oncology.

Final results of OV16, a phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel (CP) versus CP in first-line chemotherapy for advanced epithelial ovarian cancer (EOC): A GCIG study of NCIC CTG, EORTC-GCG, and GEICO.

E. Eisenhauer, D. Provencher, M. Carey, 2013 .

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP.

R. Gascoyne, L. Sehn, J. Connors, 2007 .

Which is the better surgical strategy for newly diagnosed epithelial ovarian cancer: primary or interval debulking?

P. Hoskins, 2011, Current opinion in oncology.

A North American population-based outcome for early-stage ovarian clear cell carcinoma (OCCC).

A. Tinker, K. Swenerton, C. Gilks, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Controversies in the Management of Endometrial Cancer

A. Obermair, J. Magrina, P. Hoskins, 2010, Obstetrics and gynecology international.

Limited-Stage Diffuse Large B-Cell Lymphoma (DLBCL) Patients with a Negative Pet Scan Following Three Cycles of R-CHOP Can Be Effectively Treated with Abbreviated Chemoimmunotherapy Alone.

L. Sehn, J. Connors, K. Savage, 2007 .

Transformed Lymphoma: Incidence and Long-Term Outcome.

R. Gascoyne, J. Connors, K. Savage, 2004 .

Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148.

E. Eisenhauer, A. Oza, D. Provencher, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dalteparin low molecular weight heparin (LMWH) in ovarian cancer: a phase II randomized study.

P. Liaw, L. Elit, M. Levine, 2012, Thrombosis research.